Urogenital tuberculosis
Urogenital Tuberculosis
Urogenital tuberculosis is a form of tuberculosis that affects the urinary system and the genital organs. It is a type of extrapulmonary tuberculosis, which means it occurs outside the lungs. This condition is caused by the bacterium Mycobacterium tuberculosis, the same organism responsible for pulmonary tuberculosis.
Pathophysiology
Urogenital tuberculosis typically begins as a hematogenous spread from a primary infection site, often the lungs. The bacteria can lodge in the kidneys, which are the most common site of infection in the urogenital tract. From the kidneys, the infection can spread to the ureters, bladder, and urethra. In men, it can also affect the prostate gland, seminal vesicles, and epididymis. In women, the fallopian tubes and endometrium may be involved.
Symptoms
The symptoms of urogenital tuberculosis can vary depending on the organs involved. Common symptoms include:
- Dysuria (painful urination)
- Hematuria (blood in urine)
- Flank pain
- Fever and night sweats
- Weight loss
- Infertility in both men and women
Diagnosis
Diagnosis of urogenital tuberculosis can be challenging due to its nonspecific symptoms. It often requires a combination of:
- Urine culture for Mycobacterium tuberculosis
- Polymerase chain reaction (PCR) tests
- Imaging studies such as ultrasound or CT scan
- Cystoscopy and biopsy
Treatment
The treatment of urogenital tuberculosis involves a prolonged course of antitubercular therapy (ATT), which typically includes a combination of drugs such as isoniazid, rifampicin, ethambutol, and pyrazinamide. The duration of treatment is usually 6 to 9 months, but it may be extended in complicated cases.
Prognosis
With appropriate treatment, the prognosis for urogenital tuberculosis is generally good. However, delayed diagnosis and treatment can lead to complications such as renal failure, ureteral strictures, and infertility.
Related pages
References
- World Health Organization. (2021). "Tuberculosis Fact Sheet." Retrieved from [1]
Ad. Transform your life with W8MD's Affordable GLP-1 weight loss injections from $29.99


W8MD Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss
Affordable GLP-1 Weight Loss ShotsAffordable GLP-1 Weight Loss Shots
Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:
- Semaglutide (Wegovy NYC)
- Tirzepatide (Zepbound NYC / Mounjaro)
Starting from:
- $29.99/week (Semaglutide)
- $45.00/week (Tirzepatide)
✔ Most insurances accepted for visits ✔ Prior authorization support when eligible
Start your physician weight loss NYC journey today:
📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center
📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)
Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss
|
WikiMD's Wellness Encyclopedia style="color: white; font-size: x-large; font-style: italic; background-color:#c472c4" } Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
|